P3 Health Partners (PIII) 17th Annual LD Micro Main Event Conference summary

Market environment and industry trends

• Post-pandemic pent-up demand is driving increased utilization in oncology and orthopedic care, adding volatility and downward pressure in the market.

• CMS changes, including the transition to the V28 risk assessment model and upcoming Stars program adjustments in 2026, are impacting revenue streams.

• Elevated cost of capital and rapid industry changes have altered investment strategies and created unprecedented sector challenges.

Business model and operations

• Operates across five states, managing 126,000 Medicare patients through a network of 2,900 PCPs and over 20 payer partners.

• Focuses on provider enablement in the Medicare space, emphasizing physician-led care and deep relationships with clinicians.

• Delivers value by offering clinicians resources like care managers, data analytics, and technology partnerships, notably with Innovaccer.

• Innovaccer partnership aims to enhance point-of-care solutions and integrate AI, with full implementation expected in 2025.

Financial performance and growth strategy

• Reported $1.3 billion in 2023 revenue and $135 million in medical margin, with a focus on the Quadruple Aim: outcomes, cost, quality, and clinician satisfaction.

• Growth strategy centers on increasing patient density within existing PCP panels, aiming for over 50, ideally 100, Medicare patients per PCP.

• Plans to deepen relationships with current providers to capture more of the 2 million potential Medicare lives in the network.

• Operational efficiencies and network rationalization are prioritized to improve margins and achieve cash flow and EBITDA positivity.